Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets

Xiaolei Gu, Qi Long, Qing Qi, Jing Zhou, Song Chen, Ling WangBioScience 2024 · DOI

Abstract

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Due to the complexity of the disorder and the presence of the blood-brain barrier (BBB), its drug discovery and development are facing enormous challenges, especially after several failures of monoclonal antibody (mAb) trials. Nevertheless, the Food and Drug Administration's approval of the mAb aducanumab has ushered in a new day. As we better understand the disease's pathogenesis and identify novel intracerebral therapeutic targets, antibody-based therapies have advanced over the past few years. The mAb drugs targeting β-amyloid or hyperphosphorylated tau protein are the focus of the current research. Massive neuronal loss and glial cell-mediated inflammation are also the vital pathological hallmarks of AD, signaling a new direction for research on mAb drugs. We have elucidated the mechanisms by which AD-specific mAbs cross the BBB to bind to targets. In order to investigate therapeutic approaches to treat AD, this review focuses on the promising mAbs targeting intracerebral dysfunction and related strategies to cross the BBB.

Introduction

Alzheimer’s Disease (AD) remains a formidable challenge in modern medicine, characterized by a complex interplay of amyloid-beta (Aβ) plaques, tau tangles, and chronic neuroinflammation. For decades, the field of drug development struggled through a "valley of death," marked by numerous high-profile failures in monoclonal antibody (mAb) clinical trials. These failures were largely attributed to two primary factors: the biological complexity of the disease and the delivery bottleneck created by the blood-brain barrier (BBB). The BBB is an exceptionally selective filter that prevents nearly 100% of large-molecule drugs from entering the brain, with less than 0.5% of peripherally administered mAbs typically reaching their intracerebral targets.

Pathological Mechanisms and Therapeutic Targets

The traditional "amyloid cascade hypothesis" has evolved into a more nuanced understanding of AD pathology. While Aβ often appears as an early marker, tau pathology is more closely correlated with cognitive decline. Furthermore, the role of the innate immune system—specifically microglia and astrocytes—has emerged as a critical factor. These cells can exist in neuroprotective or neuro-destructive states, often referred to as the A1/A2 phenotype.

Overview of AD pathological processes including APP cleavage, the amyloid cascade, and glial activation.

Current research focuses on several key areas:

  • Targeting Aβ: mAbs are designed to bind to various stages of Aβ formation, including monomers, oligomers, and mature plaques. Recent successes suggest that targeting the N-terminus or specific modifications like pyroglutamate is more effective than targeting mid-sequence epitopes.
  • Targeting Tau: New therapies aim to inhibit tau aggregation or clear extracellular tau fragments to prevent the "seeding" effect, where pathology spreads between neurons.
  • Modulating Neuroinflammation: Strategies are being developed to shift glial cells from a pro-inflammatory state to a neuroprotective one, potentially breaking the "vicious cycle" of inflammation and protein accumulation.

The Clinical Landscape

The recent FDA approvals of aducanumab and lecanemab have revitalized the field. Phase 3 trials for lecanemab demonstrated a 27% slowing of clinical decline, while donanemab showed significant amyloid clearance in over half of its primary cohort. Conversely, other approaches, such as BACE inhibitors designed to stop Aβ production, have largely failed, sometimes even exacerbating cognitive symptoms.

A summary of major clinical trials (Phases 1-3) as of early 2024 highlights the diversity of targets and the varying degrees of success:

Summary of monoclonal antibodies against Aβ and tau in clinical trials, detailing targets, study phases, and effectiveness.

Overcoming the Blood-Brain Barrier

The primary engineering challenge remains the efficient delivery of these large molecules across the BBB. Novel strategies include Receptor-Mediated Transcytosis (RMT), which utilizes "Brainshuttle" technology to hijack natural transport mechanisms like the transferrin receptor. Other approaches involve nanoparticles and intranasal administration to bypass the systemic circulation. Bispecific antibodies—featuring one arm for BBB transport and another for the therapeutic target—represent a promising frontier to increase brain penetration and reduce peripheral side effects.

Conclusion and Future Directions

Despite recent breakthroughs, significant gaps remain. The "decoupling" of biomarker success (clearing plaques) from clinical success (improving memory) suggests that timing is critical. Future interventions may need to start decades before symptom onset. Additionally, managing safety concerns like Amyloid-Related Imaging Abnormalities (ARIA) is essential for the widespread adoption of these therapies. As our understanding of the multi-factorial nature of AD deepens, multi-pronged therapeutic approaches targeting Aβ, tau, and neuroinflammation simultaneously may offer the best hope for patients.

Summary updated

Abstract

Alzheimer's disease (AD) is one of the most common neurodegenerative diseases. Due to the complexity of the disorder and the presence of the blood-brain barrier (BBB), its drug discovery and development are facing enormous challenges, especially after several failures of monoclonal antibody (mAb) trials. Nevertheless, the Food and Drug Administration's approval of the mAb aducanumab has ushered in a new day. As we better understand the disease's pathogenesis and identify novel intracerebral therapeutic targets, antibody-based therapies have advanced over the past few years. The mAb drugs targeting β-amyloid or hyperphosphorylated tau protein are the focus of the current research. Massive neuronal loss and glial cell-mediated inflammation are also the vital pathological hallmarks of AD, signaling a new direction for research on mAb drugs. We have elucidated the mechanisms by which AD-specific mAbs cross the BBB to bind to targets. In order to investigate therapeutic approaches to treat AD, this review focuses on the promising mAbs targeting intracerebral dysfunction and related strategies to cross the BBB.
BibTeX
@inproceedings{gu2024monoclonal,
  author = {Xiaolei Gu and Qi Long and Qing Qi and Jing Zhou and Song Chen and Ling Wang},
  title = {{Monoclonal antibody therapy for Alzheimer's disease focusing on intracerebral targets}},
  booktitle = {BioScience},
  year = {2024},
  doi = {10.5582/bst.2023.01288},
}
Figure